Abstracts tagged "psoriatic arthritis and questionnaires"

Abstract Number: 2529 • 2017 ACR/ARHP Annual Meeting
Appraisal of the Contest Questionnaire in the Screening for Psoriatic Arthritis
Amir Haddad¹, Joy Feld^1,2, Lihi Eder³, Idit Lavi⁴, Oxana Zlazhover⁵ and Devy Zisman^1,6, ¹Rheumatology Unit Carmel Medical Center, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁴Epidemiology Unit Carmel Medical Center, Haifa, Israel, ⁵Bnei Zion Medical Center, Haifa, Israel, ⁶The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Background/Purpose: Early diagnosis of psoriatic arthritis (PsA) is critical to prevent poor outcome. Several validated screening questionnaires have been developed to identify PsA patients in…
Abstract Number: 1239 • 2016 ACR/ARHP Annual Meeting
Optimizing Screening for Psoriatic Arthritis through a Shortened Psoriatic Arthritis Screening and Evaluation-2 (PASE-2) Tool
Jordan Thompson¹, Marwa Darwish², So Yeon Paek³, Joseph Merola⁴, Abrar Qureshi^1,3 and M. Elaine Husni⁵, ¹Dermatology, Alpert Medical School, Brown University, Providence, RI, ²No affiliation, Boston, MA, ³Dermatology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁴Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH
Background/Purpose: The Psoriatic Arthritis Screening and Evaluation (PASE) Tool is one of the most frequently used tools to screen psoriasis patients for signs and symptoms…
Abstract Number: 1720 • 2016 ACR/ARHP Annual Meeting
Predictive Value of Different Tools for Detection of Psoriatic Arthritis in Patients with Psoriasis in Daily Routine Care Using Questionnaires for Diagnosis of Psoriatic Arthritis and Fluorescence-Optical Imaging Technique
Michaela Koehm¹, Tanja Rossmanith², Hans-Eckhard Langer³, GR Burmester⁴, Siegfried Wassenberg⁵, Benjamin Köhler⁶, Ulrich Kaesser⁷, Marina Backhaus⁸, Harald Burkhardt⁹ and Frank Behrens⁹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵Rheumazentrum, Ratingen, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷6Internistische Praxisgemeinschaft am Krankenhaus Balserische Stiftung Gießen, Gießen, Germany, ⁸Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin disease in Europe. Psoriatic arthritis (PsA) is closely associated to Pso; the skin…
Abstract Number: 2167 • 2016 ACR/ARHP Annual Meeting
Validation of the Earp Questionnaire: Detection of Psoriatic Arthritis in the Spanish Population
juan garcia Gavin¹, Ceferino Barbazan¹, Rafael Botella², Jose Andres Roman³, david vidal⁴, Delia Reina⁴, Antonio Javier Chaves⁵, Jose Luis Alvarez⁵, Antonio Velez⁶, Maria Dolores Lopez Montilla⁶, Javier Mataix⁷, Jose Rosas⁷, Ricardo Ruiz Villaverde⁸, Rafael Caliz⁸, Miren Alustiza⁹ and Virginia Carrasco⁹, ¹Complejo Universitario Hospitalario de Vigo, Vigo, Spain, ²Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ⁴Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain, ⁵Hospital Infanta Cristina de Badajoz, Badajoz, Spain, ⁶Hospital Reina Sofía, Cordoba, Spain, ⁷Hospital de la Marina Baixa de Villajoyosa, Alicante, Spain, ⁸Hospital Virgen de las Nieves, Granada, Spain, ⁹Abbvie, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a progressive, debilitating condition. It is estimated that between 25 and 35% of patients with psoriasis may develop psoriatic arthritis…
Abstract Number: 686 • 2015 ACR/ARHP Annual Meeting
Does an Educational Leaflet Improve Attendance for Screening for Psoriatic Arthritis?
Laura C Coates, Laura J Savage, Anna R. Moverley and Philip S. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: There is a need for screening to identify patients with psoriasis who have PsA. We developed an educational leaflet about the risk of PsA…
Abstract Number: 308 • 2013 ACR/ARHP Annual Meeting
Cross-Cultural Adaptation, Validation and Reliability Of The Brazilian Version Of The Psoriatic Arthritis Screening Evaluation Tool
Roberto Ranza¹, Claudia G Schainberg², Sueli Carneiro³, Gladys Martins⁴, Jose Joaquim Rodrigues⁵, Jamille Carneiro⁶, Ricardo Romiti⁷, Thiago B. M. Barros⁸, Ana Luiza Sampaio⁹, Amanda Pedreira⁹, Carolina Z Costa¹⁰, Rogerio MC Pinto¹¹, M. Elaine Husni¹² and Abrar A. Qureshi¹³, ¹Universidade Federal de Uberlandia, Uberlandia MG, Brazil, ²Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, ⁴Dermatologia Hospital Universitario Universidade de Brasilia, Brasilia, Brazil, ⁵Dermatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, ⁶Reumatologia, Universidade de Brasilia, Brasilia, Brazil, ⁷Dermatologia Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁸Rheumatology, Reumatologia Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹Dermatologia Hospital Universitário e Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁰Reumatologia, Reumatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, ¹¹Matematica, Matematica, Universidade Federal de Uberlandia, Uberlandia, Brazil, ¹²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ¹³Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriatic Arthritis (PsA) remains an under-diagnosed disease among patients with psoriasis (PsO). Dermatologists are not routinely trained to detect musculoskeletal manifestations hence arthritis, enthesitis…
Abstract Number: 1346 • 2012 ACR/ARHP Annual Meeting
Comparison of Three Screening Tools in Psoriatic Arthritis: The Contest Study
Laura C. Coates¹, Tariq Aslam¹, A. D. Burden², Esther Burden-Teh³, Anna R. Caperon⁴, Rino Cerio⁵, Chandra Chattopadhyay⁶, Hector Chinoy⁷, Mark J. D. Goodfield⁸, Lesley Kay⁹, Bruce W. Kirkham¹⁰, Christopher R. Lovell¹¹, Helena Marzo-Ortega¹², Neil McHugh¹³, Ruth Murphy³, Costantino Pitzalis¹⁴, NJ Reynolds¹⁵, Catherine H. Smith¹⁶, Elizabeth Stewart¹⁷, Richard B. Warren¹⁸, Hilary E. Wilson¹⁹ and Philip S. Helliwell²⁰, ¹LIMM, University of Leeds, Division of Rheumatic and Musculoskeletal Disease, LIMM, University of Leeds, Leeds, United Kingdom, ²Department of Dermatology, Western Infirmary, Dumbarton Road, United Kingdom, ³Department of Dermatology, Nottingham Independent Treatment Centre, Nottingham, United Kingdom, ⁴Division of Rheumatic and Musculoskeletal Disease, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁵CMS/CAU Cutaneous Medicine and Surgery, Bart's and The London NHS Tust, United Kingdom, ⁶Department of Rheumatology, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom, ⁷Rheumatic Diseases Centre, The University of Manchester, Manchester, United Kingdom, ⁸Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁹Department of Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ¹⁰Rheum Dept/ Guys Hospital, 4th Fl Thomas Guy House, London, United Kingdom, ¹¹Department of Dermatology, Royal United Hospital, Bath, United Kingdom, ¹²Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, United Kingdom, ¹³Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom, ¹⁵Department of Dermatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ¹⁶St John's Institute of Dermatology, Guys and St Thomas' Hospital, London, ¹⁷Department of Dermatology, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom, ¹⁸Dermatology Centre, University of Manchester, Manchester, United Kingdom, ¹⁹Department of Rheumatology, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, ²⁰PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: The majority of patients with PsA have psoriasis prior to arthritis and there is evidence that a significant proportion of patients in dermatology clinics…
Abstract Number: 547 • 2012 ACR/ARHP Annual Meeting
Comparison and Validation of Screening Questionnaires for Psoriatic Arthritis in Patients with Psoriasis
Devy Zisman¹, Lihi Eder², Bosmat Zamir³, Arie Laor⁴ and Joy Feld¹, ¹Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Dermatology Service, Clalit Health Services, Haifa and Western Galilee District, Haifa, Israel, ⁴Carmel Medical Center, Haifa, Israel
Background/Purpose: Several self-administered screening questionnaires are available to identify patients suspected as suffering from psoriatic arthritis (PsA) among patients with psoriasis, thus facilitating their referral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].